H.C. Wainwright is acting as sole book running manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFFP:
- TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
- TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
- TFF Pharmaceuticals Signals Advancements in Investor Update
- TFF Pharmaceuticals files to sell 147,500 shares of common stock for holders
- TFF Pharmaceuticals announces data from TFF TAC Phase 2 trial